3SBio Inc.
1530
Classement en actions
#3760
Operating as an investment holding company, 3SBio Inc. specializes in the full... Operating as an investment holding company, 3SBio Inc. specializes in the full lifecycle of biopharmaceutical products within the People's Republic of China, encompassing research, development, manufacturing, marketing, and sales. Its diverse portfolio addresses a range of medical needs. Key therapeutic agents include TPIAO, a recombinant human thrombopoietin for chemotherapy-induced and immune thrombocytopenia; YISAIPU, a tumor necrosis factor for rheumatoid arthritis, ankylosing spondylitis, and psoriasis; and recombinant human erythropoietins EPIAO and SEPO, along with Aiyishu, to combat various forms of anemia. In oncology, Cipterbin is used for HER2-positive metastatic breast cancer in combination with chemotherapy. Intefen, a recombinant human interferon, targets lymphatic or hematopoietic malignancies and viral infections, while Inleusin, a human interleukin-2, treats renal cell carcinoma, melanoma, and thoracic fluid build-up. The company also offers Mandi for male alopecia and alopecia areata; Xenopax to prevent acute rejection post-renal transplant; Byetta for glycemic control in type 2 diabetes patients; and Qiming Keli for retinopathy linked to type 2 diabetes. SPARIN, an injectable low-molecular-weight heparin calcium, serves in the prophylaxis and treatment of deep vein thrombosis, and prevents clotting during hemodialysis. Beyond its core pharmaceutical activities, 3SBio Inc. provides additional services such as trading, project management and consultation, technology, and agricultural support. The company maintains strategic alliances with numerous prominent organizations, including AstraZeneca, Lilly, Toray Industries Inc, Samsung Bioepis, Refuge Biotechnologies, Verseau, TLC, Numab, GenSight, Sensorion, and the Dana–Farber Cancer Institute. Established in 1993, its headquarters are situated in Shenyang, People's Republic of China.
Prix de l'action
$1.75
Capitalisation boursière
$4.39B
Changement (1 jour)
-3.64%
Changement (1 an)
-50.52%
Pays
CN
Échange 3SBio Inc. (1530)
Catégorie
Healthcare
Revenus pour 3SBio Inc. (1530)
Revenus en Jun 2026 TTM : $2.58B
Selon les derniers rapports financiers de 3SBio Inc., le chiffre d'affaires actuel de l'entreprise (TTM) est de $2.58B. En 2023, l'entreprise a réalisé un chiffre d'affaires de $1.10B une augmentation par rapport à le chiffre d'affaires de l'année 2022, qui était de $994.42M. Le chiffre d'affaires correspond au revenu total généré par la vente de biens ou de services. Contrairement au bénéfice, aucune dépense n'est déduite.
Historique des revenus pour 3SBio Inc. de 2012 à 2026
Revenus à la fin de chaque année
| Année | Revenus | Changez |
|---|---|---|
| 2026 (TTM) | $2.58B | 106.76% |
| 2024 | $1.25B | 13.01% |
| 2023 | $1.10B | 11.04% |
| 2022 | $994.42M | -0.96% |
| 2021 | $1.00B | 17.39% |
| 2020 | $855.33M | 11.99% |
| 2019 | $763.73M | 14.61% |
| 2018 | $666.40M | 16.10% |
| 2017 | $573.97M | 42.46% |
| 2016 | $402.90M | 56.37% |
| 2015 | $257.65M | 41.12% |
| 2014 | $182.57M | 26.51% |
| 2013 | $144.32M | 37.16% |
| 2012 | $105.22M | 0.00% |
Revenus d’entreprises similaires ou concurrentes
| Entreprise | Revenus | Différence de revenus | Pays |
|---|---|---|---|
| $12.62B | 389.31% |
US
|
|
| $2.23B | -13.64% |
US
|
|
| $15.74B | 510.24% |
AU
|
|
| $6.02B | 133.38% |
NL
|
|
| - | - |
CH
|
